ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 109 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2016. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,928,522 | +6.1% | 1,967,879 | +50.5% | 0.00% | – |
Q2 2023 | $1,817,359 | -76.3% | 1,307,452 | -72.9% | 0.00% | – |
Q1 2023 | $7,668,869 | -77.7% | 4,823,188 | -12.5% | 0.00% | -100.0% |
Q4 2022 | $34,322,235 | +12.4% | 5,509,187 | +20.9% | 0.00% | 0.0% |
Q3 2022 | $30,542,000 | +11.8% | 4,558,644 | +6.2% | 0.00% | 0.0% |
Q2 2022 | $27,311,000 | +56.4% | 4,294,232 | +14.1% | 0.00% | – |
Q1 2022 | $17,463,000 | +55.9% | 3,763,740 | +67.9% | 0.00% | – |
Q4 2021 | $11,204,000 | -53.7% | 2,241,217 | +11.7% | 0.00% | -100.0% |
Q3 2021 | $24,173,000 | -45.2% | 2,006,134 | -3.8% | 0.00% | 0.0% |
Q2 2021 | $44,105,000 | -26.7% | 2,085,347 | -2.8% | 0.00% | -50.0% |
Q1 2021 | $60,208,000 | +12.2% | 2,146,396 | +4.0% | 0.00% | 0.0% |
Q4 2020 | $53,669,000 | -28.7% | 2,064,205 | +1.9% | 0.00% | -33.3% |
Q3 2020 | $75,293,000 | -29.8% | 2,025,704 | -3.0% | 0.00% | -25.0% |
Q2 2020 | $107,181,000 | +74.0% | 2,088,896 | +6.9% | 0.00% | +33.3% |
Q1 2020 | $61,610,000 | -50.0% | 1,953,987 | -5.5% | 0.00% | -40.0% |
Q4 2019 | $123,329,000 | +59.1% | 2,068,232 | -2.2% | 0.01% | +66.7% |
Q3 2019 | $77,540,000 | -16.0% | 2,115,163 | +6.6% | 0.00% | -25.0% |
Q2 2019 | $92,270,000 | +23.7% | 1,983,420 | +6.8% | 0.00% | +33.3% |
Q1 2019 | $74,585,000 | -13.7% | 1,857,673 | -1.1% | 0.00% | -25.0% |
Q4 2018 | $86,430,000 | +3.7% | 1,878,899 | -0.0% | 0.00% | 0.0% |
Q3 2018 | $83,367,000 | +17.8% | 1,878,905 | +4.1% | 0.00% | +33.3% |
Q2 2018 | $70,746,000 | -34.3% | 1,805,232 | +21.3% | 0.00% | -40.0% |
Q1 2018 | $107,671,000 | +8.6% | 1,488,597 | -1.1% | 0.01% | 0.0% |
Q4 2017 | $99,114,000 | +30.0% | 1,505,395 | -1.1% | 0.01% | +25.0% |
Q3 2017 | $76,267,000 | +28.9% | 1,521,674 | +19.0% | 0.00% | +33.3% |
Q2 2017 | $59,154,000 | +30.7% | 1,278,206 | -0.3% | 0.00% | +50.0% |
Q1 2017 | $45,265,000 | +110302.4% | 1,281,944 | +39211.4% | 0.00% | – |
Q4 2016 | $41,000 | -12.8% | 3,261 | -4.1% | 0.00% | – |
Q3 2016 | $47,000 | +38.2% | 3,401 | 0.0% | 0.00% | – |
Q2 2016 | $34,000 | +126.7% | 3,401 | +285.2% | 0.00% | – |
Q1 2016 | $15,000 | +87.5% | 883 | +134.2% | 0.00% | – |
Q4 2015 | $8,000 | -11.1% | 377 | 0.0% | 0.00% | – |
Q3 2015 | $9,000 | -71.0% | 377 | 0.0% | 0.00% | – |
Q2 2015 | $31,000 | -93.0% | 377 | -92.1% | 0.00% | -100.0% |
Q1 2015 | $443,000 | – | 4,776 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |